Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NOVO-B.CO Stock Summary
Top 10 Correlated ETFs
NOVO-B.CO
In the News
NOVO-B.CO Financial details
Company Rating
Strong Buy
Market Cap
3992.63B
Income
83.68B
Revenue
232.26B
Book val./share
23.8
Cash/share
6.75
Dividend
11.15
Dividend %
1.53%
Employees
63.37K
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
43.5
Forward P/E
31.77
PEG
36.89
P/S
15.15
P/B
35.23
P/C
130.56
P/FCF
41.77
Quick Ratio
0.63
Current Ratio
0.82
Debt / Equity
0.25
LT Debt / Equity
0.19
-
-
EPS (TTM)
27.4
EPS next Y
27.74
EPS next Q
5.35
EPS this Y
-23.83%
EPS next Y
1.25%
EPS next 5Y
43.61%
EPS last 5Y
17.92%
Revenue last 5Y
13.74%
Revenue Q/Q
12.14%
EPS Q/Q
-1.99%
-
-
-
-
SMA20
5.45%
SMA50
21.92%
SMA100
28.8%
Inst Own
-
Inst Trans
-
ROA
25%
ROE
87%
ROC
0.66%
Gross Margin
84%
Oper. Margin
39%
Profit Margin
35%
Payout
42%
Shs Outstand
4.5B
Shs Float
4.19B
-
-
-
-
Target Price
-
52W Range
504.4-932.0
52W High
-5.44%
52W Low
+74.86%
RSI
54
Rel Volume
0.9
Avg Volume
2.71M
Volume
2.45M
Perf Week
-2.29%
Perf Month
3.57%
Perf Quarter
35.56%
Perf Half Y
38.31%
-
-
-
-
Beta
0.175
-
-
Volatility
5.38%, 29.68%
Prev Close
0%
Price
881.3
Change
-1.53%
NOVO-B.CO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 25.65 | 27.13 | 30.57 | 38.94 | 51.67 | |
Net income per share | 8.19 | 9 | 10.37 | 12.22 | 18.62 | |
Operating cash flow per share | 9.83 | 11.1 | 11.94 | 17.36 | 24.23 | |
Free cash flow per share | 7.47 | 6.38 | 10.34 | 14.11 | 15.58 | |
Cash per share | 3.25 | 2.73 | 3.8 | 5.19 | 6.73 | |
Book value per share | 12.11 | 13.53 | 15.36 | 18.37 | 23.71 | |
Tangible book value per share | 10.88 | 9.12 | 5.99 | 7.06 | 10.27 | |
Share holders equity per share | 12.11 | 13.53 | 15.36 | 18.37 | 23.71 | |
Interest debt per share | 0.99 | 2.3 | 6.32 | 5.76 | 6.13 | |
Market cap | 919.7B | 998.34B | 1692.78B | 2131.42B | 3137.82B | |
Enterprise value | 908.71B | 995.94B | 1708.7B | 2144.55B | 3150.43B | |
P/E ratio | 23.61 | 23.69 | 35.45 | 38.39 | 37.5 | |
Price to sales ratio | 7.54 | 7.86 | 12.02 | 12.05 | 13.51 | |
POCF ratio | 19.66 | 19.22 | 30.78 | 27.02 | 28.81 | |
PFCF ratio | 25.87 | 33.42 | 35.55 | 33.23 | 44.82 | |
P/B Ratio | 15.97 | 15.77 | 23.93 | 25.53 | 29.45 | |
PTB ratio | 15.97 | 15.77 | 23.93 | 25.53 | 29.45 | |
EV to sales | 7.45 | 7.85 | 12.14 | 12.12 | 13.56 | |
Enterprise value over EBITDA | 15.72 | 16.54 | 25.29 | 26.14 | 27.89 | |
EV to operating cash flow | 19.42 | 19.17 | 31.07 | 27.19 | 28.93 | |
EV to free cash flow | 25.56 | 33.34 | 35.89 | 33.44 | 45 | |
Earnings yield | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | |
Free cash flow yield | 0.04 | 0.03 | 0.03 | 0.03 | 0.02 | |
Debt to equity | 0.08 | 0.16 | 0.38 | 0.31 | 0.25 | |
Debt to assets | 0.04 | 0.07 | 0.14 | 0.11 | 0.09 | |
Net debt to EBITDA | -0.19 | -0.04 | 0.24 | 0.16 | 0.11 | |
Current ratio | 1.06 | 0.94 | 0.86 | 0.89 | 0.82 | |
Interest coverage | 238.56 | 138.78 | 23.93 | 197.91 | 189.25 | |
Income quality | 1.2 | 1.23 | 1.15 | 1.42 | 1.3 | |
Dividend Yield | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | |
Payout ratio | 0.5 | 0.48 | 0.45 | 0.46 | 0.38 | |
Sales general and administrative to revenue | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | |
Research and developement to revenue | 0.12 | 0.12 | 0.13 | 0.14 | 0.14 | |
Intangibles to total assets | 0.05 | 0.14 | 0.22 | 0.21 | 0.19 | |
Capex to operating cash flow | -0.24 | -0.43 | -0.13 | -0.19 | -0.36 | |
Capex to revenue | -0.09 | -0.17 | -0.05 | -0.08 | -0.17 | |
Capex to depreciation | -1.98 | -3.84 | -1.23 | -2 | -4.13 | |
Stock based compensation to revenue | 0 | 0.01 | 0.01 | 0.01 | 0.01 | |
Graham number | 47.22 | 52.36 | 59.86 | 71.06 | 99.65 | |
ROIC | 0.64 | 0.55 | 0.47 | 0.53 | 0.59 | |
Return on tangible assets | 0.33 | 0.34 | 0.32 | 0.29 | 0.33 | |
Graham Net | -4.59 | -7.57 | -13.32 | -17.36 | -23.44 | |
Working capital | 3.47B | -4.46B | -13.92B | -12.75B | -30.01B | |
Tangible asset value | 51.76B | 42.67B | 27.58B | 32.07B | 46.16B | |
Net current asset value | -5.56B | -15.79B | -38.17B | -49.58B | -68.28B | |
Invested capital | 0.08 | 0.16 | 0.38 | 0.31 | 0.25 | |
Average receivables | 28.02B | 30.67B | 39.49B | 52.15B | 66.38B | |
Average payables | 6.56B | 6.04B | 7.29B | 12.23B | 20.6B | |
Average inventory | 16.99B | 18.09B | 19.08B | 22B | 28.1B | |
Days sales outstanding | 87.2 | 92.54 | 121.32 | 118.61 | 118.27 | |
Days payables outstanding | 115.53 | 99.69 | 136.85 | 199.99 | 261.32 | |
Days of inventory on hand | 320.54 | 323.22 | 302.72 | 312.91 | 324.65 | |
Receivables turnover | 4.19 | 3.94 | 3.01 | 3.08 | 3.09 | |
Payables turnover | 3.16 | 3.66 | 2.67 | 1.83 | 1.4 | |
Inventory turnover | 1.14 | 1.13 | 1.21 | 1.17 | 1.12 | |
ROE | 0.68 | 0.67 | 0.68 | 0.67 | 0.79 | |
Capex per share | -2.36 | -4.72 | -1.6 | -3.25 | -8.65 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 10.63 | 11.82 | 12.06 | 13.08 | 14.71 | |
Net income per share | 3.01 | 4.39 | 4.31 | 5.01 | 4.91 | |
Operating cash flow per share | 1.57 | 6.61 | 6.35 | 9.13 | 2.13 | |
Free cash flow per share | 0.21 | 5.54 | 4.78 | 6.76 | -1.54 | |
Cash per share | 5.21 | 6.15 | 8.09 | 10.6 | 6.75 | |
Book value per share | 18.46 | 17.7 | 20.09 | 20.72 | 23.8 | |
Tangible book value per share | 7.09 | 6.51 | 8.82 | 8.3 | 10.31 | |
Share holders equity per share | 18.46 | 17.7 | 20.09 | 20.72 | 23.8 | |
Interest debt per share | 3.92 | 5.9 | 5.77 | 6.39 | 5.56 | |
Market cap | 2121.19B | 2450.22B | 2475.08B | 2890.47B | 3125.67B | |
Enterprise value | 2134.32B | 2460.8B | 2479.21B | 2886.86B | 3138.29B | |
P/E ratio | 39.02 | 30.92 | 31.85 | 32.15 | 35.58 | |
Price to sales ratio | 44.11 | 45.91 | 45.58 | 49.22 | 47.46 | |
POCF ratio | 298.72 | 82.18 | 86.61 | 70.56 | 327.26 | |
PFCF ratio | 2.29K | 97.96 | 114.9 | 95.26 | -453.98 | |
P/B Ratio | 25.41 | 30.68 | 27.36 | 31.08 | 29.33 | |
PTB ratio | 25.41 | 30.68 | 27.36 | 31.08 | 29.33 | |
EV to sales | 44.38 | 46.11 | 45.66 | 49.15 | 47.65 | |
Enterprise value over EBITDA | 206.93 | 89.23 | 92.81 | 88.13 | 110.07 | |
EV to operating cash flow | 300.57 | 82.54 | 86.76 | 70.47 | 328.58 | |
EV to free cash flow | 2.3K | 98.38 | 115.09 | 95.14 | -455.82 | |
Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Free cash flow yield | 0 | 0.01 | 0.01 | 0.01 | 0 | |
Debt to equity | 0.31 | 0.32 | 0.28 | 0.29 | 0.25 | |
Debt to assets | 0.11 | 0.1 | 0.09 | 0.09 | 0.09 | |
Net debt to EBITDA | 1.27 | 0.38 | 0.15 | -0.11 | 0.44 | |
Current ratio | 0.89 | 0.86 | 0.88 | 0.82 | 0.82 | |
Interest coverage | -1.03 | 22.29 | 85.01 | 12.41 | -12.74 | |
Income quality | 0.52 | 1.5 | 1.47 | 1.82 | 0.43 | |
Dividend Yield | 0 | 0.01 | 0 | 0 | 0 | |
Payout ratio | 0 | 0.93 | 0 | 0.6 | 0 | |
Sales general and administrative to revenue | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | |
Research and developement to revenue | 0.17 | 0.13 | 0.13 | 0.14 | 0.16 | |
Intangibles to total assets | 0.21 | 0.2 | 0.18 | 0.19 | 0.19 | |
Capex to operating cash flow | -0.87 | -0.16 | -0.25 | -0.26 | -1.72 | |
Capex to revenue | -0.13 | -0.09 | -0.13 | -0.18 | -0.25 | |
Capex to depreciation | -3.03 | -2.79 | -3.23 | -4.21 | -5.49 | |
Stock based compensation to revenue | 0.03 | 0 | -0.08 | -0.06 | 0.36 | |
Graham number | 35.33 | 41.81 | 44.17 | 48.31 | 51.25 | |
ROIC | 0.06 | 0.19 | 0.16 | 0.18 | 0.15 | |
Return on tangible assets | 0.07 | 0.1 | 0.08 | 0.09 | 0.09 | |
Graham Net | -17.44 | -19.08 | -19.32 | -21.89 | -23.53 | |
Working capital | -12.75B | -18.02B | -19.07B | -30.35B | -30.01B | |
Tangible asset value | 32.07B | 29.39B | 39.72B | 37.27B | 46.16B | |
Net current asset value | -49.58B | -56.21B | -52.73B | -64.91B | -68.28B | |
Invested capital | 0.31 | 0.32 | 0.28 | 0.29 | 0.25 | |
Average receivables | 55.51B | 57.71B | 64.22B | 66.24B | 68.61B | |
Average payables | 11.95B | 12.82B | 13.92B | 18.95B | 22.86B | |
Average inventory | 23.81B | 25B | 26.82B | 28.78B | 30.67B | |
Days sales outstanding | 107.62 | 97.68 | 116.89 | 94.95 | 102.84 | |
Days payables outstanding | 169.79 | 110.55 | 203.78 | 186.3 | 230.13 | |
Days of inventory on hand | 265.66 | 281.76 | 321 | 273.66 | 285.9 | |
Receivables turnover | 0.84 | 0.92 | 0.77 | 0.95 | 0.88 | |
Payables turnover | 0.53 | 0.81 | 0.44 | 0.48 | 0.39 | |
Inventory turnover | 0.34 | 0.32 | 0.28 | 0.33 | 0.31 | |
ROE | 0.16 | 0.25 | 0.21 | 0.24 | 0.21 | |
Capex per share | -1.36 | -1.06 | -1.56 | -2.37 | -3.67 |
NOVO-B.CO Frequently Asked Questions
What is Novo Nordisk A/S stock symbol ?
Novo Nordisk A/S is a DK stock and trading under the symbol NOVO-B.CO
What is Novo Nordisk A/S stock quote today ?
Novo Nordisk A/S stock price is $881.3 today.
Is Novo Nordisk A/S stock public?
Yes, Novo Nordisk A/S is a publicly traded company.